ERBB2 and breast carcinoma: Also, the inhibition of FAK by the FAK inhibitor PF87 was reported to sensitize BT-474 and MDA-361 breast cancer cells to the cytotoxic effects of the anti-Her2+ breast cancer agent trastuzumab [148].